Quality of life and associated factors of heroin-dependent patients receiving methadone and buprenorphine maintenance treatment.
buprenorphine
heroin dependence
medications to treat opioid use disorder
methadone
quality of life
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
13 Dec 2023
13 Dec 2023
Historique:
revised:
07
11
2023
received:
13
07
2023
accepted:
10
11
2023
medline:
13
12
2023
pubmed:
13
12
2023
entrez:
13
12
2023
Statut:
aheadofprint
Résumé
Although studies in Western countries have investigated the quality of life (QoL) of heroin users, limited research on this topic has been conducted in Asia. The present study assessed QoL in patients with heroin dependence receiving medications to treat opioid use disorder. We performed a cross-sectional study of patients with heroin dependence receiving methadone and buprenorphine treatment. The demographic and substance use variables of patients receiving methadone and buprenorphine were compared. The Chinese Health Questionnaire (CHQ-12), Obsessive Compulsive Drug Use Scale (OCDUS), and World Health Organization Quality of Life Short Form Taiwan version (WHOQOL-BREF-T) were administered to measure patient mental health problems, addiction severity, and QoL, respectively. Multivariate regression was used to identify the factors associated with QoL. A total of 149 patients receiving methadone and 31 receiving buprenorphine completed the questionnaires. Individuals in the buprenorphine group were more likely to be married (p = 0.024) or employed (p = 0.024), have a higher educational level (p = 0.013), have lower drug craving (OCDUS: p = 0.035), or have higher QoL (WHOQOL-BREF-T: p = 0.004) than those in the methadone group. After adjustment for other variables, employment was positively associated with the physical, psychological, and environmental domains of QoL. Receiving buprenorphine treatment (p = 0.032) and longer treatment duration (p = 0.016) were associated with higher psychological QoL. Several factors were associated with QoL in patients with heroin dependence. Some measures may improve their QoL, such as reducing employment barriers, improving treatment adherence, or increasing accessibility to buprenorphine treatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Taipei City Hospital
ID : 10601-62-025
Organisme : Taipei City Hospital
ID : 11201-62-025
Organisme : National Science and Technology Council
ID : 112-2314-B-532-003
Informations de copyright
© 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
Références
Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Psychiatry. 2018;5(12):987-1012.
Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32-51.
Smyth B, Hoffman V, Fan J, Hser Y-I. Years of potential life lost among heroin addicts 33 years after treatment. Prev Med. 2007;44(4):369-374.
Chang K-C, Lu T-H, Lee K-Y, Hwang J-S, Cheng C-M, Wang J-D. Estimation of life expectancy and the expected years of life lost among heroin users in the era of opioid substitution treatment (OST) in Taiwan. Drug Alcohol Depend. 2015;153:152-158.
Chang K-C, Lee K-Y, Lu T-H, Hwang J-S, Lin C-N, Ting S-Y, et al. Opioid agonist treatment reduces losses in quality of life and quality-adjusted life expectancy in heroin users: evidence from real world data. Drug Alcohol Depend. 2019;201:197-204.
Van Hecke N, Claes C, Vanderplasschen W, De Maeyer J, De Witte N, Vandevelde S. Conceptualisation and measurement of quality of life based on Schalock and Verdugo's model: a cross-disciplinary review of the literature. Social Indic Res. 2018;137:335-351.
Bray JW, Aden B, Eggman AA, Hellerstein L, Wittenberg E, Nosyk B, et al. Quality of life as an outcome of opioid use disorder treatment: a systematic review. J Subst Abuse Treat. 2017;76:88-93.
Karow A, Verthein U, Pukrop R, Reimer J, Haasen C, Krausz M, et al. Quality of life profiles and changes in the course of maintenance treatment among 1,015 patients with severe opioid dependence. Subst Use Misuse. 2011;46(6):705-715.
De Maeyer J, Vanderplasschen W, Broekaert E. Quality of life among opiate-dependent individuals: a review of the literature. Int J Drug Policy. 2010;21(5):364-380.
Millson P, Challacombe L, Villeneuve PJ, Strike CJ, Fischer B, Myers T, et al. Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. Eur Addict Res. 2006;12(2):74-82.
Karow A, Verthein U, Krausz M, Schäfer I. Association of personality disorders, family conflicts and treatment with quality of life in opiate addiction. Eur Addict Res. 2008;14(1):38-46.
Astals M, Domingo-Salvany A, Buenaventura CC, Tato J, Vazquez JM, Martin-Santos R, et al. Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment. Subst Use Misuse. 2008;43(5):612-632.
Fei JTB, Yee A, Habil MHB, Danaee M. Effectiveness of methadone maintenance therapy and improvement in quality of life following a decade of implementation. J Subst Abuse Treat. 2016;69:50-56.
Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O'Grady KE, Olsen YK, et al. Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use. J Psychoactive Drugs. 2015;47(2):149-157.
Giacomuzzi S, Riemer Y, Ertl M, Kemmler G, Rössler H, Hinterhuber H, et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction. 2003;98(5):693-702.
Giacomuzzi SM, Ertl M, Kemmler G, Riemer Y, Vigl A. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. Scientific World Journal. 2005;5:452-468.
Maremmani I, Pani PP, Pacini M, Perugi G. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat. 2007;33(1):91-98.
Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse. 2007;33(5):631-642.
Angell B, Muhunthan J, Eades A-M, Cunningham J, Garvey G, Cass A, et al. The health-related quality of life of indigenous populations: a global systematic review. Qual Life Res. 2016;25:2161-2178.
Koekenbier K, Leino-Kilpi H, Cabrera E, Istomina N, Stark ÅJ, Katajisto J, et al. Empowering knowledge and its connection to health-related quality of life: a cross-cultural study: a concise and informative title: empowering knowledge and its connection to health-related quality of life. Appl Nurs Res. 2016;29:211-216.
Morling B, Lamoreaux M. Measuring culture outside the head: a meta-analysis of individualism-collectivism in cultural products. Pers Soc Psychol Rev. 2008;12(3):199-221.
Simha A, Ahmed S, Prasad R, Dinesh AS, Kandasamy A, Rao NP. Effect of national cultural dimensions and consumption rates on stigma toward alcohol and substance use disorders. Int J Soc Psychiatry. 2022;68(7):1411-1417.
Lyu S-Y, Su L-W, Chen Y-MA. Effects of education on harm-reduction programmes. Lancet. 2012;379(9814):e28-e30.
Lee S-F, Hsu J, Tsay W-I. The trend of drug abuse in Taiwan during the years 1999 to 2011. J Food Drug Analysis. 2013;21(4):390-396.
Chen J-s. Studying up harm reduction policy: the office as an assemblage. Int J Drug Policy. 2011;22(6):471-477.
Muller AE, Skurtveit S, Clausen T. Performance of the WHOQOL-BREF among Norwegian substance use disorder patients. BMC Med Res Methodol. 2019;19(1):1-9.
Yao G, Chung C-W, Yu C-F, Wang J-D. Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version. J Formos Med Assoc. 2002;101(5):342-351.
Chen K-H, Wu C-H, Yao G. Applicability of the WHOQOL-BREF on early adolescence. Soc Indic Res. 2006;79:215-234.
Chien C-W, Wang J-D, Yao G, Hsueh I-P, Hsieh C-L. Agreement between the WHOQOL-BREF Chinese and Taiwanese versions in the elderly. J Formos Med Assoc. 2009;108(2):164-169.
Lin C-Y, Hwang J-S, Wang W-C, Lai W-W, Su W-C, Wu T-Y, et al. Psychometric evaluation of the WHOQOL-BREF, Taiwan version, across five kinds of Taiwanese cancer survivors: Rasch analysis and confirmatory factor analysis. J Formos Med Assoc. 2019;118(1):215-222.
Yang S-C, Kuo P-W, Wang J-D, Lin M-I, Su S. Quality of life and its determinants of hemodialysis patients in Taiwan measured with WHOQOL-BREF (TW). Am J Kidney Dis. 2005;46(4):635-641.
Chang KC, Wang JD, Tang HP, Cheng CM, Lin CY. Psychometric evaluation, using Rasch analysis, of the WHOQOL-BREF in heroin-dependent people undergoing methadone maintenance treatment: further item validation. Health Qual Life Outcomes. 2014;12:148.
Goldberg DP, Blackwell B. Psychiatric illness in general practice: a detailed study using a new method of case identification. Br Med J. 1970;2(5707):439-443.
Cheng TA, Wu J, Chong M, Williams P. Internal consistency and factor structure of the Chinese health questionnaire. Acta Psychiatr Scand. 1990;82(4):304-308.
Zhang C-C, Hou L-H, Zheng X, Lu J, Zou J-Y, Qian Y, et al. Factor structure of 12 items in the Chinese health questionnaire among the elderly population in mainland China. Public Health. 2020;187:143-149.
Anton RF, Moak DH, Latham P. The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995;19(1):92-99.
Franken IH, Hendriks VM, van den Brink W. Initial validation of two opiate craving questionnaires: the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav. 2002;27(5):675-685.
Randall-Kosich O, Andraka-Christou B, Totaram R, Alamo J, Nadig M. Comparing reasons for starting and stopping methadone, buprenorphine, and naltrexone treatment among a sample of white individuals with opioid use disorder. J Addict Med. 2020;14(4):e44-e52.
Barrau K, Thirion X, Micallef J, Chuniaud-Louche C, Bellemin B, San Marco JL. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction. 2001;96(10):1433-1441.
Madden A, Lea T, Bath N, Winstock AR. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev. 2008;27(6):671-678.
Lin C-Y, Li Y-P, Lin S-I, Chen C-H. Measurement equivalence across gender and education in the WHOQOL-BREF for community-dwelling elderly Taiwanese. Int Psychogeriatr. 2016;28(8):1375-1382.
Sordo L, Chahua M, Bravo MJ, Barrio G, Brugal MT, Domingo-Salvany A, et al. Depression among regular heroin users: the influence of gender. Addict Behav. 2012;37(1):148-152.
De Maeyer J, Vanderplasschen W, Lammertyn J, van Nieuwenhuizen C, Sabbe B, Broekaert E. Current quality of life and its determinants among opiate-dependent individuals five years after starting methadone treatment. Qual Life Res. 2011;20:139-150.
Chang KC, Wang JD, Saxon A, Matthews AG, Woody G, Hser YI. Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan. Int J Drug Policy. 2017;43:1-6.
Lee CT, Chen VC, Tan HK, Chou SY, Wu KH, Chan CH, et al. Suicide and other-cause mortality among heroin users in Taiwan: a prospective study. Addict Behav. 2013;38(10):2619-2623.
Wang GY, Wouldes TA, Russell BR. Methadone maintenance treatment and cognitive function: a systematic review. Curr Drug Abuse Rev. 2013;6(3):220-230.
Tanner GR, Bordon N, Conroy S, Best D. Comparing methadone and Suboxone in applied treatment settings: the experiences of maintenance patients in Lanarkshire. J Subst Abus. 2011;16(3):171-178.
Gryczynski J, Jaffe JH, Schwartz RP, Dusek KA, Gugsa N, Monroe CL, et al. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013;22(3):285-291.
Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39(4):340-352.
Hallinan R, Byrne A, Agho K, McMahon C, Tynan P, Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008;5(3):684-692.
Quaglio G, Lugoboni F, Pattaro C, Melara B, Mezzelani P, Des Jarlais DC. Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment. Drug Alcohol Depend. 2008;94(1-3):12-18.
Serafini G, Adavastro G, Canepa G, De Berardis D, Valchera A, Pompili M, et al. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int J Mol Sci. 2018;19(8):2410.
Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785-e793.
Dean AJ, Bell J, Christie MJ, Mattick RP. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry. 2004;19(8):510-513.
Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 2004;75(1):37-45.
Guillery SPE, Hellweg R, Kronenberg G, Bohr U, Kunte H, Enge S. Quality of life in opioid replacement therapy: a naturalistic cross-sectional comparison of methadone/levomethadone, buprenorphine, and diamorphine patients. Eur Addict Res. 2021;27(5):371-380.
Henkel D. Unemployment and substance use: a review of the literature (1990-2010). Curr Drug Abuse Rev. 2011;4(1):4-27.
Diener E. Subjective well-being. Psychol. Bull. 1984;95(3):542.
Diener E, Seligman ME. Beyond money: Toward an economy of well-being. Psychological science in the public interest. 2004;5(1):1-31.
Tang TLP. Income and quality of life: Does the love of money make a difference? J. Bus. Ethics. 2011;72:375-393.